Celcuity

Celcuity Short-term Debt

The Short-Term Debt of Celcuity (CELC) as of Nov 11, 2026 is 54,000.00 USD. In the previous year, Short-Term Debt was 171,952.00 USD — a change of -68.60% (lower).

Short-term Debt

54,000.00USD

YoY

-68.60%

Last updated:

Short-Term Debt of Celcuity is 2025 54,000.00 USD. Short-Term Debt of Celcuity was 2024 171,952.00 USD. It decreases by -68.60% lower compared to the previous year.

The Celcuity Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
5,730.00 USD
Jan 1, 2019
184,235.00 USD
Jan 1, 2020
193,328.00 USD
Jan 1, 2021
195,708.00 USD
Jan 1, 2022
194,198.00 USD
Jan 1, 2023
184,950.00 USD
Jan 1, 2024
171,952.00 USD
Jan 1, 2025
54,000.00 USD
The Celcuity Short-term Debt history
YEARShort-term DebtYoY
54,000.00USD-68.60%
171,952.00USD-7.03%
184,950.00USD-4.76%
194,198.00USD-0.77%
195,708.00USD+1.23%
193,328.00USD+4.94%
184,235.00USD+3,115.27%
5,730.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Short-Term Debt of Celcuity is 54,000.00 USD in 2025.

Short-Term Debt of Celcuity changed from 171,952.00 USD to 54,000.00 USD, representing a -68.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Celcuity since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Celcuity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Celcuity

All Key Metrics — Celcuity